Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
Conditions studied
Triple Negative Breast Cancer
About this study
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
Interventions
- Other: Imaging assessment — The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
Primary outcomes
- concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC). (two weeks after surgery)
Eligibility information
Study locations
- Centre Henri Becquerel, Rouen, 76038 France
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-05.